Ceftriaxone

Lyme Polyradiculitis, Chancroid, Whipple Disease + 33 more

Treatment

24 FDA approvals

20 Active Studies for Ceftriaxone

What is Ceftriaxone

Ceftriaxone

The Generic name of this drug

Treatment Summary

Ceftriaxone is an antibiotic used to treat a wide range of bacterial infections. It is a third-generation cephalosporin that has a long half-life, which means it can be taken once or twice a day. It is especially effective against multi-drug resistant bacteria and has a relatively low risk of side effects. Ceftriaxone is better at fighting Gram-negative bacteria compared to other cephalosporin antibiotics, but it is not as effective against Staphylococcus aureus.

Rocephin

is the brand name

image of different drug pills on a surface

Ceftriaxone Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Rocephin

Ceftriaxone

1993

165

Approved as Treatment by the FDA

Ceftriaxone, commonly known as Rocephin, is approved by the FDA for 24 uses including Gonorrhea and Bacterial Infections .

Gonorrhea

Bacterial Infections

Lower respiratory tract infection bacterial

bacterial otitis media

uncomplicated Gonorrhea

complicated Bacterial Urinary Tract Infections

Skin and Subcutaneous Tissue Bacterial Infections

Sepsis Bacterial

Abdominal Infection

Bone and Joint Infections

prophylaxis of Postoperative Infections

uncomplicated Urinary tract infection bacterial

Urinary Tract Infection (UTI)

Meningitis, Bacterial

Bacterial Infections

Sepsis

Osteomyelitis

Intraabdominal Infections

Urinary Tract Infections

Urinary Tract Infections

Postoperative Infections

Bacteria

Otitis Media

Pelvic Inflammatory Disease

Effectiveness

How Ceftriaxone Affects Patients

Ceftriaxone is an antibiotic used to treat bacterial infections that are usually caused by certain types of bacteria. It works by stopping the growth of bacteria and is resistant to many different types of enzymes that bacteria can produce. When taking ceftriaxone, it should not be mixed with any liquids that contain calcium, as it can cause the drug to turn into a solid. Taking ceftriaxone can also lead to a buildup of small stones in the gallbladder or bile duct.

How Ceftriaxone works in the body

Ceftriaxone stops the growth of bacterial cells by blocking the formation of protective walls around them. It does this by stopping certain enzymes in the bacterial cell membrane from working properly, which prevents the cell wall from forming. Without this wall, the bacteria are unable to survive and die off.

When to interrupt dosage

The endorsed dose of Ceftriaxone is contingent upon the diagnosed condition, including Otitis Media, Conjunctivitis and Sepsis Bacterial. The quantity of dosage also fluctuates based upon the administration strategy (e.g. Powder, for solution or Solution) featured in the table beneath.

Condition

Dosage

Administration

Sepsis

100.0 mg/mL, , 2000.0 mg, 500.0 mg, 250.0 mg, 200.0 mg/mL, 1000.0 mg, 10000.0 mg, 100000.0 mg

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular, Injection, powder, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous, Kit - Intramuscular; Intravenous, Kit, Kit - Intramuscular; Intravenous; Topical, Intramuscular; Intravenous; Topical

Sinusitis

100.0 mg/mL, , 2000.0 mg, 500.0 mg, 250.0 mg, 200.0 mg/mL, 1000.0 mg, 10000.0 mg, 100000.0 mg

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular, Injection, powder, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous, Kit - Intramuscular; Intravenous, Kit, Kit - Intramuscular; Intravenous; Topical, Intramuscular; Intravenous; Topical

Gonococcal arthritis

100.0 mg/mL, , 2000.0 mg, 500.0 mg, 250.0 mg, 200.0 mg/mL, 1000.0 mg, 10000.0 mg, 100000.0 mg

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular, Injection, powder, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous, Kit - Intramuscular; Intravenous, Kit, Kit - Intramuscular; Intravenous; Topical, Intramuscular; Intravenous; Topical

Shigellosis

100.0 mg/mL, , 2000.0 mg, 500.0 mg, 250.0 mg, 200.0 mg/mL, 1000.0 mg, 10000.0 mg, 100000.0 mg

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular, Injection, powder, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous, Kit - Intramuscular; Intravenous, Kit, Kit - Intramuscular; Intravenous; Topical, Intramuscular; Intravenous; Topical

Gonorrhea

100.0 mg/mL, , 2000.0 mg, 500.0 mg, 250.0 mg, 200.0 mg/mL, 1000.0 mg, 10000.0 mg, 100000.0 mg

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular, Injection, powder, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous, Kit - Intramuscular; Intravenous, Kit, Kit - Intramuscular; Intravenous; Topical, Intramuscular; Intravenous; Topical

Pelvic Inflammatory Disease

100.0 mg/mL, , 2000.0 mg, 500.0 mg, 250.0 mg, 200.0 mg/mL, 1000.0 mg, 10000.0 mg, 100000.0 mg

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular, Injection, powder, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous, Kit - Intramuscular; Intravenous, Kit, Kit - Intramuscular; Intravenous; Topical, Intramuscular; Intravenous; Topical

Arthritis, Infectious

100.0 mg/mL, , 2000.0 mg, 500.0 mg, 250.0 mg, 200.0 mg/mL, 1000.0 mg, 10000.0 mg, 100000.0 mg

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular, Injection, powder, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous, Kit - Intramuscular; Intravenous, Kit, Kit - Intramuscular; Intravenous; Topical, Intramuscular; Intravenous; Topical

Community Acquired Pneumonia (CAP)

100.0 mg/mL, , 2000.0 mg, 500.0 mg, 250.0 mg, 200.0 mg/mL, 1000.0 mg, 10000.0 mg, 100000.0 mg

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular, Injection, powder, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous, Kit - Intramuscular; Intravenous, Kit, Kit - Intramuscular; Intravenous; Topical, Intramuscular; Intravenous; Topical

Lyme Polyradiculitis

100.0 mg/mL, , 2000.0 mg, 500.0 mg, 250.0 mg, 200.0 mg/mL, 1000.0 mg, 10000.0 mg, 100000.0 mg

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular, Injection, powder, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous, Kit - Intramuscular; Intravenous, Kit, Kit - Intramuscular; Intravenous; Topical, Intramuscular; Intravenous; Topical

Epiglottitis

100.0 mg/mL, , 2000.0 mg, 500.0 mg, 250.0 mg, 200.0 mg/mL, 1000.0 mg, 10000.0 mg, 100000.0 mg

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular, Injection, powder, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous, Kit - Intramuscular; Intravenous, Kit, Kit - Intramuscular; Intravenous; Topical, Intramuscular; Intravenous; Topical

Epididymitis

100.0 mg/mL, , 2000.0 mg, 500.0 mg, 250.0 mg, 200.0 mg/mL, 1000.0 mg, 10000.0 mg, 100000.0 mg

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular, Injection, powder, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous, Kit - Intramuscular; Intravenous, Kit, Kit - Intramuscular; Intravenous; Topical, Intramuscular; Intravenous; Topical

Bacteria

100.0 mg/mL, , 2000.0 mg, 500.0 mg, 250.0 mg, 200.0 mg/mL, 1000.0 mg, 10000.0 mg, 100000.0 mg

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular, Injection, powder, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous, Kit - Intramuscular; Intravenous, Kit, Kit - Intramuscular; Intravenous; Topical, Intramuscular; Intravenous; Topical

Vulvovaginitis

100.0 mg/mL, , 2000.0 mg, 500.0 mg, 250.0 mg, 200.0 mg/mL, 1000.0 mg, 10000.0 mg, 100000.0 mg

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular, Injection, powder, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous, Kit - Intramuscular; Intravenous, Kit, Kit - Intramuscular; Intravenous; Topical, Intramuscular; Intravenous; Topical

Urinary Tract Infections

100.0 mg/mL, , 2000.0 mg, 500.0 mg, 250.0 mg, 200.0 mg/mL, 1000.0 mg, 10000.0 mg, 100000.0 mg

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular, Injection, powder, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous, Kit - Intramuscular; Intravenous, Kit, Kit - Intramuscular; Intravenous; Topical, Intramuscular; Intravenous; Topical

Syphilis

100.0 mg/mL, , 2000.0 mg, 500.0 mg, 250.0 mg, 200.0 mg/mL, 1000.0 mg, 10000.0 mg, 100000.0 mg

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular, Injection, powder, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous, Kit - Intramuscular; Intravenous, Kit, Kit - Intramuscular; Intravenous; Topical, Intramuscular; Intravenous; Topical

Urinary Tract Infections

100.0 mg/mL, , 2000.0 mg, 500.0 mg, 250.0 mg, 200.0 mg/mL, 1000.0 mg, 10000.0 mg, 100000.0 mg

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular, Injection, powder, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous, Kit - Intramuscular; Intravenous, Kit, Kit - Intramuscular; Intravenous; Topical, Intramuscular; Intravenous; Topical

Intraabdominal Infections

100.0 mg/mL, , 2000.0 mg, 500.0 mg, 250.0 mg, 200.0 mg/mL, 1000.0 mg, 10000.0 mg, 100000.0 mg

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular, Injection, powder, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous, Kit - Intramuscular; Intravenous, Kit, Kit - Intramuscular; Intravenous; Topical, Intramuscular; Intravenous; Topical

Conjunctivitis

100.0 mg/mL, , 2000.0 mg, 500.0 mg, 250.0 mg, 200.0 mg/mL, 1000.0 mg, 10000.0 mg, 100000.0 mg

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular, Injection, powder, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous, Kit - Intramuscular; Intravenous, Kit, Kit - Intramuscular; Intravenous; Topical, Intramuscular; Intravenous; Topical

prophylaxis of Bacterial endocarditis

100.0 mg/mL, , 2000.0 mg, 500.0 mg, 250.0 mg, 200.0 mg/mL, 1000.0 mg, 10000.0 mg, 100000.0 mg

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular, Injection, powder, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous, Kit - Intramuscular; Intravenous, Kit, Kit - Intramuscular; Intravenous; Topical, Intramuscular; Intravenous; Topical

Neisseria

100.0 mg/mL, , 2000.0 mg, 500.0 mg, 250.0 mg, 200.0 mg/mL, 1000.0 mg, 10000.0 mg, 100000.0 mg

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular, Injection, powder, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous, Kit - Intramuscular; Intravenous, Kit, Kit - Intramuscular; Intravenous; Topical, Intramuscular; Intravenous; Topical

Warnings

Ceftriaxone Contraindications

Condition

Risk Level

Notes

Hyperbilirubinemia

Do Not Combine

calcium-containing IV solution requirement

Do Not Combine

There are 20 known major drug interactions with Ceftriaxone.

Common Ceftriaxone Drug Interactions

Drug Name

Risk Level

Description

Neomycin

Major

The risk or severity of nephrotoxicity can be increased when Ceftriaxone is combined with Neomycin.

Tenofovir

Major

Ceftriaxone may increase the nephrotoxic activities of Tenofovir.

Tenofovir alafenamide

Major

Ceftriaxone may increase the nephrotoxic activities of Tenofovir alafenamide.

Tenofovir disoproxil

Major

Ceftriaxone may increase the nephrotoxic activities of Tenofovir disoproxil.

Vibrio cholerae CVD 103-HgR strain live antigen

Major

The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Ceftriaxone.

Ceftriaxone Toxicity & Overdose Risk

Taking too much ceftriaxone may increase the chances of developing kidney stones, which can lead to kidney failure. Other symptoms of overdose are not known, but may be similar to the side effects of the drug. If a ceftriaxone overdose occurs, supportive treatment should be given as dialysis will not remove the drug from the body.

image of a doctor in a lab doing drug, clinical research

Ceftriaxone Novel Uses: Which Conditions Have a Clinical Trial Featuring Ceftriaxone?

12 active trials are underway to examine the potential of Ceftriaxone in treating Postoperative Infections, uncomplicated Bacterial Urinary Tract Infections and Whipple Disease.

Condition

Clinical Trials

Trial Phases

Whipple Disease

0 Actively Recruiting

Sinusitis

0 Actively Recruiting

Prosthetic Joint Infections

2 Actively Recruiting

Phase 4, Not Applicable

Epididymitis

0 Actively Recruiting

Postoperative Infections

0 Actively Recruiting

Abscess

0 Actively Recruiting

Conjunctivitis

0 Actively Recruiting

Intraabdominal Infections

1 Actively Recruiting

Not Applicable

Meningitis, Bacterial

0 Actively Recruiting

Otitis Media

0 Actively Recruiting

Urinary Tract Infections

0 Actively Recruiting

Community Acquired Pneumonia (CAP)

5 Actively Recruiting

Not Applicable, Phase 1, Phase 3

Gonorrhea

0 Actively Recruiting

Bacterial Infections

0 Actively Recruiting

Neisseria

0 Actively Recruiting

Arthritis, Infectious

0 Actively Recruiting

Urinary Tract Infection (UTI)

6 Actively Recruiting

Phase 1, Phase 3, Phase 4, Phase 2

prophylaxis of Postoperative Infections

0 Actively Recruiting

Osteomyelitis

0 Actively Recruiting

Vulvovaginitis

0 Actively Recruiting

Ceftriaxone Reviews: What are patients saying about Ceftriaxone?

5

Patient Review

1/27/2008

Ceftriaxone for Middle Ear Infection

This was a lifesaver when my twins both had double ear infections. The amoxicillin didn't work, so our doctor gave them each a shot. They slept great that night and were back to their normal selves the next day. So much easier than having to remember to give them medicine multiple times a day for 10 days!

5

Patient Review

11/29/2007

Ceftriaxone for Bone Infection caused by Staphylococcus Aureus Bacteria

I developed a serious infection after two failed surgeries to correct my pectus excavatum. My surgeon had to place metal plates in my chest and the wound was weeping fluids for weeks. I started weekly injections of cefatriaxone and things went very well. The wound healed in just a few days and I was back to normal within a week.

4

Patient Review

5/11/2009

Ceftriaxone for Bacterial Meningitis

A single 2 gm dose really helped me out and eased my condition within a night.

4

Patient Review

9/15/2017

Ceftriaxone for Lyme Disease

I had recurrant Lyme disease which oral antibiotics like Doxycycline and Tetracycline couldn't help. After a month of getting medicine through an arm cath though, I was feeling much better. I was more tired than before and needed lots of sleep, but it was worth finally getting rid of the Lyme. There are some lasting side effects from chronic Lyme, but this treatment did its job.

2.3

Patient Review

2/11/2012

Ceftriaxone for Urinary Tract Infection due to E. Coli Bacteria

I've had chronic UTIs for years now and haven't found a medication that really works. I've been to many doctors, both in Florida and Michigan, and no one has been able to help me.

1

Patient Review

3/27/2008

Ceftriaxone for Bacterial Pneumonia caused by Staphylococcus

Worked well for me.

1

Patient Review

10/11/2009

Ceftriaxone for Pneumonia caused by Bacteria

I had an allergic reaction to this medication that started in mid-August and is still ongoing as of this writing. My skin was covered with a "cobblestone appearance" and severe redness and itching. After two months, the condition is still present. Additionally, it has been difficult to walk and handle objects comfortably. I would never recommend this product for anyone.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about ceftriaxone

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the drug ceftriaxone used for?

"Ceftriaxone is used to treat bacterial infections in many different parts of the body. It is also given before certain types of surgery to prevent infections. Ceftriaxone belongs to the class of medicines known as cephalosporin antibiotics. It works by killing bacteria or preventing their growth."

Answered by AI

What bacteria is killed by ceftriaxone?

"Ceftriaxone not only eliminates some of the primary agents of respiratory tract infections, but also common hospital superbugs. This makes it a powerful tool in the fight against these diseases."

Answered by AI

Is ceftriaxone a strong antibiotic?

"Ceftriaxone (Rocephin) is a strong antibiotic that works against a good number of bacteria, but there are other antibiotics that can treat more types of infections or more serious infections."

Answered by AI

Is ceftriaxone a penicillin drug?

"Ceftriaxone is an antibiotic that can be used to treat various types of bacterial infections. This includes infections in the lower respiratory tract, skin, urinary tract, pelvic region, blood, and joints. Additionally, it can be used to treat bacterial meningitis."

Answered by AI

Clinical Trials for Ceftriaxone

Image of University of Miami Health System in Miami, United States.

Antibiotic-Coated Sutures for Prosthetic Joint Infections

18 - 89
All Sexes
Miami, FL

The purpose of this study is to evaluate whether the use of antibiotic-coated (triclosan) braided sutures is non-inferior or potentially superior to standard monofilament sutures in patients with prosthetic joint infections (PJIs) managed with the DAIR protocol. Several studies in various surgical specialties have demonstrated the effectiveness and non-inferiority of triclosan-coated braided sutures in infected surgical cases, and the study intends to transpose this idea to the management of prosthetic joint infections. Monofilament sutures are the present standard of care in any infected joint case due their lower surface area for bacterial harborization, though surgeons sacrifice mechanical integrity and comfortability with the closure in the process. By demonstrating the safety of antibiotic -coated braided sutures, surgeons will no longer have to make this compromise.

Waitlist Available
Has No Placebo

University of Miami Health System

Colin McNamara, MD

Image of Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18) in Pittsburgh, United States.

VLA15 Vaccine for Lyme Disease

18 - 44
All Sexes
Pittsburgh, PA

The purpose of this study is to learn about the safety and effects of the Lyme disease vaccine (called VLA15) when given at different time points. This study is seeking participants who: * are generally healthy and between 18 and 44 years of age, * have never had a vaccine for Lyme disease before, * are not currently taking, or haven't recently taken, medicines like chemotherapy, blood products, or blood thinners, and * are not pregnant or breastfeeding and do not plan to become pregnant while receiving the study vaccine. All participants in this study will receive a total of 5 doses through a shot in the upper arm. Four doses will be the study vaccine (VLA15), and 1 dose will be saltwater. The study will compare the experiences of people receiving the study vaccine at different time points. This will help see if the study vaccine is safe and will help understand its effect on the body. Participants will take part in this study for about 2 years. During this time, the participants will have 11 planned visits - 8 will be at the study clinic and 3 will be done over the phone. The clinic visits may include having a health check, giving a small amount of blood (about 20 mL or 4 teaspoons), and getting the study vaccine or saltwater as a shot.

Phase 3
Recruiting

Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18) (+4 Sites)

Pfizer CT.gov Call Center

Pfizer

Have you considered Ceftriaxone clinical trials?

We made a collection of clinical trials featuring Ceftriaxone, we think they might fit your search criteria.
Go to Trials
Image of Children's Healthcare of Atlanta in Atlanta, United States.

Antibiotic Strategies for Pneumonia in Children

12 - 71
All Sexes
Atlanta, GA

The goal of this clinical trial is to determine if a "watch and wait" antibiotic strategy, called Safety Net Antibiotic Prescribing (SNAP), can safely reduce unnecessary antibiotic use while ensuring that children diagnosed with community-acquired pneumonia get better from their illness. The main aims of this study are: * To compare the effectiveness of SNAP versus immediate antibiotic prescribing in children with mild community-acquired pneumonia (CAP) * To identify which patient groups benefit most from the SNAP strategy * To identify factors that shape implementation of each prescribing strategy. Researchers will compare the SNAP strategy (where parents or guardians are instructed to give antibiotics only if their child is not improving after 72 hours, or sooner if they are worsening) to the immediate antibiotic prescribing strategy (where parents or guardians are instructed to give the antibiotics right after their healthcare visit) to see if one strategy is more effective than the other. Participants will be randomly assigned to either the immediate antibiotic group or the SNAP group at enrollment. Participation lasts 14 days with follow-up surveys at 4, 7, and 14 days after enrollment.

Recruiting
Has No Placebo

Children's Healthcare of Atlanta (+3 Sites)

Todd Florin, MD, MSCE

Image of Maternity Centre of Hamilton in Hamilton, Canada.

Rapid Test for Syphilis

13 - 49
All Sexes
Hamilton, Canada

The goal of this clinical trial is to learn if a finger-prick blood test for rapid diagnosis of syphilis infection can be implemented in a low-barrier prenatal clinic for people at risk of syphilis in pregnancy. The test gives results in 5 minutes and also tests for HIV. The main questions the study aims to answer are: * How often do pregnant people at risk of syphilis agree to the rapid test? * How well do healthcare providers perform the rapid test? * Does the rapid test speed up diagnosis and treatment of syphilis in pregnant people and their sexual partners? Participants will: * Give feedback about why they did or did not want to take the rapid test, and what their experience was taking the test; and * Share information about their health, pregnancy, and syphilis treatment (if applicable).

Recruiting
Has No Placebo

Maternity Centre of Hamilton

Laura K Erdman, MD PhD FRCPC

Have you considered Ceftriaxone clinical trials?

We made a collection of clinical trials featuring Ceftriaxone, we think they might fit your search criteria.
Go to Trials
Image of Harbor UCLA Medical Center - Medicine - Infectious Diseases in Torrance, United States.

Optimized Beta-lactam Dosing for Bacterial Infections

18+
All Sexes
Torrance, CA

The purpose of this study is to evaluate the abilities of Cystatin C (CysC) and CysC-based estimated Glomerular Filtration Rate (eGFR) equations to characterize the pharmacokinetics (PK) profiles of meropenem and cefepime relative to Serum Creatinine (SCR), Serum Creatinine based Equation (SCRE)and iohexol at the population and individual levels in critically ill adult patients with suspected or documented AMR Gram-negative infections. We hypothesize that CysC and CysC-based eGFR equations will characterize the PK profiles of meropenem and cefepime at the population and individual levels with greater accuracy and precision than SCR and SCREs. Iohexol will be administered to patients enrolled in the study and serve as the reference indicator of measured Glomerular Filtration Rate (mGFR), which is the gold standard assessment of kidney function. We hypothesize that the predictive performances of CysC and CysC-based eGFR equations in estimating the PK profiles of meropenem and cefepime at the population and individual levels will be comparable to iohexol. The information obtained in this study will be used to develop PK/pharmacodynamics (PD) optimized meropenem and cefepime dosing schemes based on the renal function biomarker population PK (PopPK) model with the best predictive performance for clinical use in the treatment of critically ill adult patients with suspected or documented AMR Gram-negative infections and varying degrees of renal function. The primary objective of this study is to compare the abilities of renal function biomarkers (CysC, CysC-based eGFR equations, SCR, SCREs) relative to iohexol to characterize the PK profiles of meropenem and cefepime in critically ill adult patients with suspected or documented AMR Gram-negative infections.

Phase 4
Recruiting

Harbor UCLA Medical Center - Medicine - Infectious Diseases (+9 Sites)

Image of Public Health Sexual Health Clinic in Seattle, United States.

Doxycycline for Syphilis

18+
All Sexes
Seattle, WA

The goal of this clinical trial is to learn if doxycycline taken as 200mg daily for 14 days is effective to treat early stage syphilis. This is different from how doxycycline is typically used for syphilis because the full doxycycline dose will be taken at the same time of day, rather than split up into a twice daily regimen. Lab data support that taking the medication as a single daily dose should be effective as treatment, but it has not been studied clinically. The main question this study aims to answer is: Is doxycycline taken as a single daily dose of 200mg for 14 days an effective treatment for early syphilis based on a combined outcome of clinical improvement and blood test improvement? Participants will: 1. Take doxycycline 200mg daily for 14 days 2. Submit oral and rectal swabs that test for syphilis bacteria every other day for 2 weeks, returned by mail 3. Complete 2 brief online surveys over the first 2 weeks 4. Return to the clinic for an interview and blood draw every 3 months for a maximum of 3 study visits, including the first visit The investigators will compare the percentage of participants in the study who have response to treatment by 6 months to that of persons who have received standard (CDC-recommended) regimens. To do this, the investigators will calculate response percentage estimates following a shot of long-acting penicillin or 14 days of doxycycline 100mg twice daily from 60-person samples from the sexual health program's records.

Phase 2
Recruiting

Public Health Sexual Health Clinic

Travis Hunt, MD

Have you considered Ceftriaxone clinical trials?

We made a collection of clinical trials featuring Ceftriaxone, we think they might fit your search criteria.
Go to Trials